Huang Y, Hung S, Lee C, Wu N, Hui R, Tsai T
Am J Clin Dermatol. 2024; 25(6):997-1008.
PMID: 39283586
DOI: 10.1007/s40257-024-00887-8.
Kim J, Lee J, Li X, Kunjravia N, Rambhia D, Cueto I
Front Immunol. 2023; 14:1250504.
PMID: 37781383
PMC: 10536146.
DOI: 10.3389/fimmu.2023.1250504.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C
Cochrane Database Syst Rev. 2023; 7:CD011535.
PMID: 37436070
PMC: 10337265.
DOI: 10.1002/14651858.CD011535.pub6.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C
Cochrane Database Syst Rev. 2022; 5:CD011535.
PMID: 35603936
PMC: 9125768.
DOI: 10.1002/14651858.CD011535.pub5.
Tian D, Lai Y
JID Innov. 2022; 2(3):100116.
PMID: 35601055
PMC: 9121322.
DOI: 10.1016/j.xjidi.2022.100116.
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.
Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C
Am J Clin Dermatol. 2022; 23(4):433-447.
PMID: 35489008
PMC: 9055370.
DOI: 10.1007/s40257-022-00679-y.
Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis.
Meng J, Li Y, Fischer M, Steinhoff M, Chen W, Wang J
Front Immunol. 2021; 12:696784.
PMID: 34276687
PMC: 8278285.
DOI: 10.3389/fimmu.2021.696784.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C
Cochrane Database Syst Rev. 2021; 4:CD011535.
PMID: 33871055
PMC: 8408312.
DOI: 10.1002/14651858.CD011535.pub4.
Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1.
Cantrell W, Lee P, Mendelsohn A, Rozzo S, Liao W
J Eur Acad Dermatol Venereol. 2021; 35(8):e526-e528.
PMID: 33460505
PMC: 8359438.
DOI: 10.1111/jdv.17124.
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C
Cochrane Database Syst Rev. 2020; 1:CD011535.
PMID: 31917873
PMC: 6956468.
DOI: 10.1002/14651858.CD011535.pub3.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball A, Papp K, Reich K, Gooderham M, Li Q, Cichanowitz N
Br J Dermatol. 2019; 182(6):1359-1368.
PMID: 31487406
PMC: 7317753.
DOI: 10.1111/bjd.18484.
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Frieder J, Kivelevitch D, Menter A
Ther Adv Chronic Dis. 2018; 9(1):5-21.
PMID: 29344327
PMC: 5761942.
DOI: 10.1177/2040622317738910.
